Co-Diagnostics Receivables

Co-Diagnostics (CODX) currently reports a receivables of $52K as of June 2026. That compares with $210K in the prior-year period — down 75.3% year over year. Use the charts on this page to explore Co-Diagnostics's receivables history and peer comparisons.

Co-Diagnostics's receivables decreased from $210K to $52K — a 75.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Co-Diagnostics reported $52K in receivables as of June 2026. That compares with $210K in the prior-year period — down 75.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $52K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Co-Diagnostics, and consider following CODX for alerts when major investors trade the stock.

Co-Diagnostics is classified in the Healthcare sector. On receivables, it currently shows $52K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CODX with unrelated industries.